A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK726701A | GSK726701A is a prostaglandin E2 receptor 4 (EP4) partial agonist with pEC50 value of 7.4. Synonyms: {4-[4,9-Bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid. Grade: 98%. CAS No. 945721-87-9. Molecular formula: C24H22FNO5. Mole weight: 423.43. |  |
| GSK761 | GSK761 is a selective inhibitor of speckled 140 kDa (SP140) with an IC50 value of 77.79 nM. GSK761 reduces monocyte-to-inflammatory macrophage differentiation and lipopolysaccharide (LPS)-induced inflammatory activation. GSK761 induces the production of CD206+ regulatory macrophages by inhibiting SP140[1]. Uses: Scientific research. Group: Signaling pathways. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-148591. |  |
| GSK778 | GSK778 (iBET-BD1) is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively. GSK778 phenocopies the effects of pan-BET inhibitors in cancer models[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: iBET-BD1. CAS No. 2451862-42-1. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-136570. | |
| GSK778 | GSK778 is a potent and selective inhibitor of bromodomain (BRD) BD1, with IC50s of 75 nM (BRD2 BD1). GSK778 phenocopies the effects of pan-BET inhibitors in cancer models. Synonyms: GSK-778; GSK 778; iBET-BD1. Grade: 99%. CAS No. 2451862-42-1. Molecular formula: C30H33N5O3. Mole weight: 511.63. | |
| GSK 789472 hydrochloride | GSK 789472 hydrochloride is a selective dopamine D3 receptor antagonist and D2 partial agonist (pEC50 values are <5.5 and 8.3, respectively). GSK 789472 exhibits selectivity against the D4 receptor in both agonist and antagonist assays. Synonyms: GSK 789472 hydrochloride; GSK-789472 hydrochloride; GSK789472 hydrochloride; 4,5-Dihydro-1-phenyl-3-(2-piperidinyl)methylimidazol-2(1H)-one hydrochloride; 1-phenyl-3-(piperidin-2-ylmethyl)imidazolidin-2-one hydrochloride. Grade: ≥99% by HPLC. CAS No. 1257326-24-1. Molecular formula: C15H21N3O.HCl. Mole weight: 295.81. | |
| GSK 789472 hydrochloride | GSK 789472 hydrochloride. Group: Biochemicals. Grades: Purified. CAS No. 1257326-24-1. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| GSK-7975A | GSK-7975A is a potent and orally available CRAC channel inhibitor. Uses: Scientific research. Group: Signaling pathways. CAS No. 1253186-56-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12507. | |
| GSK-7975A | This active molecular is a calcium release-activated calcium modulator (ORAI1) inhibitor. GSK-7975A inhibited toxin-induced activation of ORAI1 and/or activation of Ca(2+) currents after Ca(2+) release in mouse and human pancreatic acinar cells. GSK-7975A may be used for the treatment of pancreatitis in the future. Uses: Pancreatitis. Synonyms: GSK-7975A; GSK 7975A; GSK7975A; GSK-7975; GSK 7975; GSK7975. SCHEMBL705705; AOB4124; CPYTVBALBFSXSH-UHFFFAOYSA-N; 2,6-difluoro-N-[1-[[4-hydroxy-2-(trifluoromethyl)phenyl]methyl]pyrazol-3-yl]benzamide. Grade: 98%. CAS No. 1253186-56-9. Molecular formula: C18H12F5N3O2. Mole weight: 397.31. | |
| GSK805 | GSK805 is an orally active and CNS penetrant ROR?t inhibitor. GSK805 inhibits ROR? and Th17 cells differentiation with pIC50 values of 8.4 and >8.2. GSK805 inhibits the function of Th17 cells. GSK805 can be used for the research of immunity[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1426802-50-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12776. | |
| GSK805 | GSK805 Inhibitor. Uses: Scientific use. Product Category: T7388. CAS No. 1426802-50-7. |  |
| GSK837149 | GSK837149 is a selective inhibitor of human fatty acid synthase (FAS; Ki value 30 nM) that acts via suppressing the β-ketoacyl reductase activity of the enzyme. Synonyms: GSK837149A; GSK-837149-A; GSK 837149 A; 1,3-bis[4-[(4-methylpyrimidin-2-yl)sulfamoyl]phenyl]urea. Grade: 99%. CAS No. 13616-29-0. Molecular formula: C23H22N8O5S2. Mole weight: 554.6. | |
| GSK837149A | ?98% (HPLC), solid. Group: Fluorescence/luminescence spectroscopy. |  |
| GSK840 | GSK840 is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which suppressed recombinant RIP3 kinase activity with IC50 of 0.3 nM. Synonyms: GSK 840; GSK-840. Grade: >98%. CAS No. 2361146-30-5. Molecular formula: C21H23N3O3. Mole weight: 365.4. | |
| GSK840 | GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 0.9 nM, and inhibits kinase activity with an IC50 of 0.3 nM[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK'840. CAS No. 2361146-30-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-104021. | |
| GSK-843 | GSK-843 is a potent and selective receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with IC50 of 8.6 nM. Synonyms: GSK843; GSK 843. Grade: >98%. CAS No. 1601496-05-2. Molecular formula: C19H15N5S2. Mole weight: 377.5. | |
| GSK-843 | GSK-843 (GSK'843) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 8.6 nM, and inhibits kinase activity with an IC50 of 6.5 nM. GSK-843 can be used for the research of inflammation[1][2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK'843. CAS No. 1601496-05-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-125402. | |
| GSK-8573 | GSK-8573 is an inactive control of GSK-2801, which is a potent inhibitor of BAZ2A and BAZ2B bromodomains. Synonyms: GSK8573; GSK 8573; GSK-8573; 1-[1-(3-Methoxyphenyl)-7-propoxyindolizin-3-yl]ethanone. CAS No. 1693766-04-9. Molecular formula: C20H21NO3. Mole weight: 323.392. | |
| GSK8612 | GSK8612 is a novel potent and highly selective TBK1 inhibitor, displaying an excellent selectivity profile and therefore represents an ideal probe to further dissect the biology of TBK1 in models of immunity, neuroinflammation, obesity, or cancer. Synonyms: GSK-8612; GSK 8612. CAS No. 2361659-62-1. Molecular formula: C17H17BrF3N7O2S. Mole weight: 520.33. | |
| GSK8612 | GSK8612 is a highly selective and potent Tank-binding Kinase-1 (TBK1) inhibitor, with a pIC50 of 6.8 for recombinant TBK1[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2361659-62-1. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111941. | |
| GSK864 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK864 | GSK864 is a cell penetrant, selective allosteric inhibitor of isocitrate dehydrogenase 1 (IDH1) mutant with IC50 values of 8.8, 15.2 and 16.6 nM for IDH1 mutants R132C, R132H, and R132G, respectively. Synonyms: (7S)-1-[(4-fluorophenyl)methyl]-3-N-(4-methoxy-3,5-dimethylphenyl)-7-methyl-5-(1H-pyrrole-2-carbonyl)-4,6-dihydropyrazolo[4,3-c]pyridine-3,7-dicarboxamide; GSK 864; GSK-864. CAS No. 1816331-66-4. Molecular formula: C30H31FN6O4. Mole weight: 558.6. | |
| GSK-872 | GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury[1][2][3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1346546-69-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101872. | |
| GSK'872 | GSK'872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with high affinity (IC50=1.8 nM), and is approximately >1,000-fold selective over 300 kinases in a fluorescence polarization assay at a concentration of 1 μM. Besides, GSK'872 inhibits kinase activity (IC50=1.3 nM). Synonyms: GSK872; GSK-872; GSK 872; N-(6-propan-2-ylsulfonylquinolin-4-yl)-1,3-benzothiazol-5-amine. CAS No. 1346546-69-7. Molecular formula: C19H17N3O2S2. Mole weight: 383.49. | |
| GSK-872 hydrochloride | GSK-872 hydrochloride is an RIPK3 inhibitor. It binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. Grade: 99%. CAS No. 2703752-81-0. Molecular formula: C19H18ClN3O2S2. Mole weight: 419.95. | |
| GSK-872 hydrochloride | GSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury[1][2][3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2703752-81-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101872A. | |
| GSK894490A | GSK894490A is a non-peptide ghrelin receptor agonist. It crosses the blood/brain barrier and elicit pro-cognitive effects in recognition and spatial learning and memory tests. It may be used as a potential drug target for therapeutic approaches to treat diseases affecting cognition. Uses: Gsk894490a may be used as a potential drug target for therapeutic approaches to treat diseases affecting cognition. Synonyms: Benzenesulfonamide, N-(5-((3R,5S)-3,5-dimethyl-1-piperazinyl)-2-methoxyphenyl)-4-(5-methyl-2-furanyl)-, hydrochloride (1:1), rel-; N-[5-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-methoxyphenyl]-4-(5-methylfuran-2-yl)benzenesulfonamide hydrochloride; GSK-894490A. Grade: >98 %. CAS No. 1012035-06-1. Molecular formula: C24H30ClN3O4S. Mole weight: 492.03. | |
| GSK 9027 | GSK 9027 is a glucocorticoid receptor agonist (pIC50 = 8) inhibiting production of the proinflammatory mediator IL-6 in vivo. GSK 9027 is used for the treatment of acute and chronic inflammatory conditions. Synonyms: GSK 9027; GSK9027; GSK-9027; N-[4-[1-(4-Fluorophenyl)-1H-indazol-5-yl-3-(trifluoromethyl)phenyl]benzenesulfonamide. Grade: ≥98% by HPLC. CAS No. 1229096-88-1. Molecular formula: C27H19F4N3O2S. Mole weight: 525.52. | |
| GSK923295 | GSK923295. Group: Biochemicals. Alternative Names: GSK-923295, 3-chloro-N- [ (2S) -1- [ [2- (dimethylamino) acetyl]amino]-3- [4- [8- [ (1S) -1hydroxyethyl]imidazo [1, 2-a]pyridin-2-yl]phenyl]propan-2-yl]-4-propan-2-yloxybenzamide. CAS No. 1088965-37-0. Pack Sizes: 5mg, 50mg. Molecular Formula: C32 H38 ClN 5O4 , Molecular Weight: 592.1. US Biological Life Sciences. | Worldwide |
| GSK-923295 | GSK-923295 is a special, allosteric inhibitor of centromere-associated protein-E (CENP-E) kinesin motor ATPase activity, with Ki of 3.2±0.2 nM and 1.6± 0.1 nM for human and canine, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1088965-37-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10299. | |
| GSK-923295 | GSK-923295 is a novel antimitotic inhibitor of centromere-associated protein E (CENP-E) with potential anticancer activity. GSK-923295 demonstrated significant antitumor activity against solid tumor models, inducing CRs in Ewing sarcoma, rhabdoid, and rhabdomyosarcoma xenografts. Clinical study showed that GSK-923295 had dose-proportional pharmacokinetics and a low number of grade 3 or 4 adverse events. The observed incidence of myelosuppression and neuropathy was low. Further investigations may provide a more complete understanding of the potential for GSK-923295 as an antiproliferative agent. Synonyms: GSK923295; GSK 923295; GSK-923295; GSK-923295A; GSK923295A; GSK 923295A. Grade: 98%. CAS No. 1088965-37-0. Molecular formula: C32H38ClN5O4. Mole weight: 592.14. | |
| GSK9311 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK 9311 hydrochloride | GSK9311 is a potent inhibitor of the BRPF bromodomain with pIC50 values of 6.0 and 4.3 for BRPF1 and BRPF2, respectively. GSK 9311 is a negative control for the SGC epigenetic probe GSK6853. Synonyms: N-[2,3-Dihydro-1,3-dimethyl-6-[(2R)-2-methyl-1-piperazinyl]-2-oxo-1H-benzimidazol-5-yl]-N-ethyl-2-methoxybenzamide hydrochloride. Grade: ≥98% by HPLC. CAS No. 1923851-49-3. Molecular formula: C24H31N5O3·HCl. Mole weight: 474. | |
| GSK9311 hydrochloride | GSK9311 hydrochloride is a less active analogue of GSK6853 and can be used as a negative control. It inhibits BRPF bromodomain with pIC50s of 6.0 and 4.3 for BRPF1 and BRPF2, respectively. Synonyms: N-{1,3-Dimethyl-6-[(2R)-2-methyl-1-piperazinyl]-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl}-N-ethyl-2-methoxybenzamide hydrochloride (1:1); N-[2,3-Dihydro-1,3-dimethyl-6-[(2R)-2-methyl-1-piperazinyl]-2-oxo-1H-benzimidazol-5-yl]-N-ethyl-2-methoxybenzamide hydrochloride; Benzamide, N-[2,3-dihydro-1,3-dimethyl-6-[(2R)-2-methyl-1-piperazinyl]-2-oxo-1H-benzimidazol-5-yl]-N-ethyl-2-methoxy-, hydrochloride (1:1). CAS No. 2253733-09-2. Molecular formula: C24H32ClN5O3. Mole weight: 474.00. | |
| GSK962 | GSK962 is an inactive enantiomer of GSK963, a novel highly potent and selective RIP1 inhibitor. Synonyms: GSK 962; GSK-962. Grade: >98%. CAS No. 2049872-86-6. Molecular formula: C14H18N2O. Mole weight: 230.31. | |
| GSK 962040 | GSK 962040 is a selective motilin receptor agonist with pEC50 value of 7.9. It is effective as a stimulant of human and rabbit gastrointestinal motility. lt represents a new opportunity as a treatment in diabetic gastroparesis. It is discovered as a therapeutic agent for conditions associated with delayed gastric emptying. It is highly selective against motilin receptor over the human ghrelin receptor and hERG. It also has no significant activity against other receptors including 5-HT, adrenergic, dopamine, histamine and adenosine receptors. It is found to enhance the EFS-induced cholinergic contraction and cause a small muscle contraction at high concentration in rabbit isolated gastric antrum. It also induces the contraction of human-isolated stomach preparations at 10μM. It had no significant activity at a range of other receptors (including ghrelin), ion channels and enzymes in vitro. It was preferred because its initial IC50 values at CYP3A4 were significantly higher than our preferred threshold of 10 μM. It induced phasic contractions, the duration of which was dose-related. It strongly facilitated cholinergic activity in the antrum, with lower activity in fundus and small intestine only. It was developed by glaxosmithkline and has been in Cilinic Phase 2. Uses: Gsk 962040 may be used as a treatment in diabetic gastroparesis. Synonyms: GSK-962040; GSK 962040; GSK962040; Camicinal; 1-[4-(3-fluoroanilino)piperidin-1- | |
| GSK 962040 hydrochloride | GSK 962040 hydrochloride is the hydrochloride form of GSK 962040, which is a selective motilin receptor agonist with pEC50 value of 7.9. It may be used as a treatment in diabetic gastroparesis. It was developed by glaxosmithkline and has been in Cilinic Phase 2. Uses: Gsk 962040 hydrochloride was developed by glaxosmithkline and has been in cilinic phase 2. Synonyms: Camicinal hydrochloride; GSK-962040 hydrochloride; GSK 962040 hydrochloride; GSK962040 hydrochloride; 2-[4-(3-Fluoroanilino)piperidin-1-yl]-1-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]ethanone hydrochloride. Grade: >98%. CAS No. 923565-22-4. Molecular formula: C25H34ClFN4O. Mole weight: 461.02. | |
| GSK963 | GSK963 is a chiral, highly potent and selective inhibitor of RIP1 kinase , with an IC 50 of 29 nM. GSK963 is a selective and potent inhibitor of necroptosis in murine and human cells in vitro [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2049868-46-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-103028A. | |
| GSK963 | GSK963 is a potent and selective inhibitor of RIP1 kinase (RIPK1; IC50=29 nM in FP binding assays). GSK963 displays >10?000-fold selective for RIP1 over 339 other kinases. Synonyms: 2,2-dimethyl-1-[(3S)-3-phenyl-3,4-dihydropyrazol-2-yl]propan-1-one. Grade: ≥98%. CAS No. 2049868-46-2. Molecular formula: C14H18N2O. Mole weight: 230.31. | |
| GSK983 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK984 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-A1 | GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIII?) inhibitor with a pIC50 of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC50 of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1416334-69-4. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-125118. | |
| GSK-F1 | PI4KA inhibitor-F1 is a potent PI4KA inhibitor. Synonyms: PI4KA inhibitor-F1. Grade: 98%. CAS No. 1384097-27-1. Molecular formula: C27H18F5N5O4S. Mole weight: 603.5. | |
| GSK J1 | GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases. Synonyms: GSKJ1; GSKJ 1; GSKJ-1. Grade: 98%. CAS No. 1373422-53-7. Molecular formula: C22H23N5O2. Mole weight: 389.45. | |
| GSK-J1 | GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A , with IC 50 of 60 nM towards KDM6B. Uses: Scientific research. Group: Signaling pathways. CAS No. 1373422-53-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15648. | |
| GSK-J1 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-J1 lithium salt | GSK-J1 lithium salt is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with an IC50 of 60 nM towards KDM6B. Synonyms: Lithium 3-{[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]amino}propanoate; β-Alanine, N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-, lithium salt (1:1). Molecular formula: C22H22LiN5O2. Mole weight: 395.38. | |
| GSK-J1 sodium salt | GSK-J1 is a potent and selective inhibitor of the H3K27 histone demethylases JMJD3 and UTX (IC50s = 18 and 56 μM, respectively; IC50 = 60 nM in JMJD3 antibody-based assays). Synonyms: N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanine, monosodium salt. Grade: ≥95%. CAS No. 1797832-71-3. Molecular formula: C22H22N5O2·Na. Mole weight: 411.4. | |
| GSK-J1 Sodium Salt | GSK-J1 Sodium Salt. Group: Biochemicals. Alternative Names: 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate Monosodium Salt. Grades: Highly Purified. Pack Sizes: 5mg. Molecular Formula: C22H22N5NaO2, Molecular Weight: 411.43. US Biological Life Sciences. | Worldwide |
| GSK-J2 | GSK-J2 is an isomer of GSK-J1 that does not have any specific activity. GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A. Uses: Scientific research. Group: Signaling pathways. CAS No. 1394854-52-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15648A. | |
| GSK-J2 | GSK-J2, a benzazepin derivative, has been found to have poor activity as a JMJD3 inhibitor so that could be used in the biological study of GSK-J1 as a negative control. IC50: > 100 μM. Uses: Gsk-j2 has been found to have poor activity as a jmjd3 inhibitor so that could be used in the biological study of gsk-j1 as a negative control. Synonyms: SK-J2; GSK J2; GSKJ2; 1394854-52-4; SCHEMBL15937902; 3705AH. Grade: 98%. CAS No. 1394854-52-4. Molecular formula: C22H23N5O2. Mole weight: 389.45. | |
| GSK-J2 sodium salt | GSK-J2 is a pyridine regio-isomer of GSK-J1 which poorly inhibits JMJD3 with an IC50 value greater than 100 μM. Synonyms: 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-3-yl)pyrimidin-4-yl)amino)propanoic acid, monosodium salt. Grade: ≥90%. CAS No. 2108665-15-0. Molecular formula: C22H23N5O2·Na. Mole weight: 412.4. | |
| GSK-J4 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-J4 | GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC 50 s of 8.6 and 6.6 μM, respectively. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with an IC 50 of 9 μM. GSK J4 is a cell permeable proagent of GSK-J1 [1] [2] [3]. GSK-J4 induces endoplasmic reticulum stress-related apoptosis [4]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1373423-53-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15648B. | |
| GSK-J4 | GSK-J4 Inhibitor. Uses: Scientific use. Product Category: T3100. CAS No. 1373423-53-0. | |
| GSK-J4 free base | GSK-J4 is a cell permeable, potent and selective histone demethylase. GSK-J4 is a prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family. GSK-J4 is used to probe the consequences of demethylation of H3K27me3. GSK-J4 inhibits the lipopolysaccharide-induced production of cytokines, including pro-inflammatory tumour necrosis factor (TNF). Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK-J4 free base; GSK-J-4; GSK-J 4; GSK-J4. Product Category: Others. Appearance: Solid powder. CAS No. 1373423-53-0. Molecular formula: C24H27N5O2. Mole weight: 417.51. Purity: >98%. IUPACName: ethyl 3-((2-(pyridin-2-yl)-6-(1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)pyrimidin-4-yl)amino)propanoate. Canonical SMILES: O=C(OCC)CCNC1=NC(C2=NC=CC=C2)=NC(N3CCC4=CC=CC=C4CC3)=C1. Product ID: ACM1373423530. Alfa Chemistry ISO 9001:2015 Certified. |  |
| GSK J4 HCl | GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family. Synonyms: GSK-J4; 1373423-53-0; GSK J4; Ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoateethyl 3-[[2-pyridin-2-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoate. Grade: >98%. CAS No. 1373423-53-0. Molecular formula: C24H27N5O2.HCl. Mole weight: 453.96. | |
| GSK-J4 hydrochloride | GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC 50 s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC 50 of 9 μM. GSK-J4 hydrochloride is a cell permeable proagent of GSK-J1 [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1797983-09-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-15648F. | |
| GSK-J4 hydrochloride | GSK-J4 (hydrochloride) is an ethyl ester derivative of GSK-J1 which blocks demethylation of histone H3K27 with an IC50 value greater than 50 μM in vitro. Synonyms: N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanine, ethyl ester, monohydrochloride. Grade: ≥95%. CAS No. 1797983-09-5. Molecular formula: C24H27N5O2·HCl. Mole weight: 454. | |
| GSK-J4 Hydrochloride | GSK-J4 Hydrochloride. Group: Biochemicals. Alternative Names: Ethyl 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate Monohydrochloride. Grades: Highly Purified. Pack Sizes: 5mg. Molecular Formula: C24H28ClN5O2, Molecular Weight: 453.96. US Biological Life Sciences. | Worldwide |
| GSK-J5 hydrochloride | GSK-J5 is a pyridine regio-isomer of GSK-J4 and it is a weak inhibitor of JMJD3 (IC50 > 100 μM), making it an ideal inactive control molecule for elucidating the functional role of JMJD3 inhibition. Synonyms: N-[2-(3-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanine, ethyl ester, monohydrochoride. Grade: ≥95%. CAS No. 1797983-32-4. Molecular formula: C24H27N5O2·HCl. Mole weight: 454. | |
| GSK-J5 Hydrochloride | GSK-J5 Hydrochloride is a selective jumonji H3K27 demethylase inhibitor that modulates the proinflammatory macrophage response. The histone H3 lysine 27 (H3K27) demethylase JMJD3 plays important roles in the transcriptional regulation of cell differentiation, development, the inflammatory response, and cancer.1,2 GSK-J4 (Item No. 12073) is a cell-permeable prodrug which is modified by intracellular esterases to give GSK-J1 (Item No. 12054), an inhibitor of JMJD3. GSK-J5 is a pyridine regio-isomer of GSK-J4. Like GSK-J4, this isomer is cell-permeable and hydrolyzed to a free base.3 However, the free base is a weak inhibitor of JMJD3 (IC50 > 100 μM), making it an ideal inactive control molecule for elucidating the functional role of JMJD3 inhibition.3. Group: Biochemicals. Alternative Names: N-[2-(3-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]- β-alanineEthyl Ester Hydochloride. Grades: Highly Purified. CAS No. 1394854-51-3. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| GSK-LSD1 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-LSD1 2HCl | GSK-LSD1 2HCl is an irreversible, and selective LSD1 inhibitor with IC50 of 16 nM, > 1000 fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B). Synonyms: GSK LSD1 2HCl; GSK-LSD1 Dihydrochloride. Grade: >98%. CAS No. 1431368-48-7. Molecular formula: C14H22Cl2N2. Mole weight: 289.24. | |
| GSK-LSD1 dihydrochloride | GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC50 of 16 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 2102933-95-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-100546A. | |
| GSK PERK Inhibitor | GSK PERK Inhibitor is an inhibitors of PERK, an important transmembrane protein of endoplasmic reticulum (ER). GSK PERK Inhibitor can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways. As a result, GSK PERK Inhibitor has potential use in the treatment of diseases such as Alzheimer's disease, stroke, Type 1 diabetes, Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and arrhythmias, and more specifically cancers of the breast, colon, pancreatic, and lung. Group: Biochemicals. Alternative Names: 1-[5- (4-Amino-7-methyl-7H-pyrrolo[2, 3-d]pyrimidin-5-yl) -2, 3-dihydro-1H-indol-1-yl]-2-[3-fluoro-5- (trifluoromethyl) phenyl]ethanone; 3-Fluoro-GSK2606414. Grades: Highly Purified. CAS No. 1337531-89-1. Pack Sizes: 1mg, 2mg, 5mg, 10mg. US Biological Life Sciences. | Worldwide |
| GSK PERK Inhibitor-d3 | GSK PERK Inhibitor-d3. Group: Biochemicals. Alternative Names: 1-[5- (4-Amino-7-methyl-7H-pyrrolo[2, 3-d]pyrimidin-5-yl) -2, 3-dihydro-1H-indol-1-yl]-2-[3-fluoro-5- (trifluoromethyl) phenyl]ethanone-d3; 3-Fluoro-GSK2606414-d3. Grades: Highly Purified. Pack Sizes: 1mg. Molecular Formula: C24H16D3F4N5O, Molecular Weight: 472.45. US Biological Life Sciences. | Worldwide |
| GsMTx4 | GsMTx4 is a mechanosensitive and stretch-activated ion channel inhibitor. It is used as a tool for identifying the role of these excitatory MSCs in normal physiology and pathology. Grade: >98%. CAS No. 1209500-46-8. Molecular formula: C185H273N49O45S6. Mole weight: 4095.86. | |
| GsMTx4 | GsMTx4 is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. GsMTx4 also blocks cation-selective stretch-activated channels (SACs) , attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity. GsMTx4 is an important pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology [1] [2] [4]. Uses: Scientific research. Group: Peptides. CAS No. 1209500-46-8. Pack Sizes: 500 μg; 1 mg; 5 mg. Product ID: HY-P1410. | |
| GsMTx4 TFA | GsMTx4 is a TRPC1 and TRPC6 blocker, and also blocks stretch-activated cation channels in astrocytes, cardiac cells, and skeletal muscle cells. Synonyms: H-Gly-Cys-Leu-Glu-Phe-Trp-Trp-Lys-Cys-Asn-Pro-Asn-Asp-Asp-Lys-Cys-Cys-Arg-Pro-Lys-Leu-Lys-Cys-Ser-Lys-Leu-Phe-Lys-Leu-Cys-Asn-Phe-Ser-Phe-OH.TFA; glycyl-L-cysteinyl-L-leucyl-L-alpha-glutamyl-L-phenylalanyl-L-tryptophyl-L-tryptophyl-L-lysyl-L-cysteinyl-L-asparagyl-L-prolyl-L-asparagyl-L-alpha-aspartyl-L-alpha-aspartyl-L-lysyl-L-cysteinyl-L-cysteinyl-L-arginyl-L-prolyl-L-lysyl-L-leucyl-L-lysyl-L-cysteinyl-L-seryl-L-lysyl-L-leucyl-L-phenylalanyl-L-lysyl-L-leucyl-L-cysteinyl-L-asparagyl-L-phenylalanyl-L-seryl-L-phenylalanine trifluoroacetic acid. Molecular formula: C185H278N48O46S6. Mole weight: 4103. | |
| GsMTx4 TFA | GsMTx4 TFA Inhibitor. Uses: Scientific use. Product Category: TP1300. CAS No.: | |
Our database is helping our users find suppliers everyday.
